Novartis Ag (NVS) Cash & Current Investments (2009 - 2026)
Novartis Ag (NVS) posted Cash & Current Investments of $100.0 million for Q1 2026, down 96.34% sequentially from $2.7 billion in Q4 2025, and up 370.27% YoY from $21.3 million in Q1 2025.
Novartis Ag (NVS) Cash & Current Investments (2009 - 2026) Analysis & Trends
Novartis Ag (NVS) has 16 years of Cash & Current Investments data on file, last reported at $100.0 million in Q1 2026.
- Quarterly Cash & Current Investments rose 370.27% year-over-year to $100.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $520.0 million (down 59.12% YoY) and the FY2025 annual result came in at $2.7 billion, up 901.47% from the prior year.
- Cash & Current Investments fell to $100.0 million in Q1 2026 per NVS's latest filing, from $2.7 billion in the prior quarter.
- The five-year high for Cash & Current Investments was $18.9 billion in Q4 2022, with the low at -$13.1 billion in Q2 2022.
- Average Cash & Current Investments over 5 years is $2.8 billion, with a median of $273.0 million recorded in 2024.
- Year-over-year, Cash & Current Investments sank 25672.55% in 2022 and jumped 908.6% in 2023.
- Novartis Ag's Cash & Current Investments stood at $18.9 billion in 2022, then slumped by 32.64% to $12.8 billion in 2023, then sank by 97.86% to $273.0 million in 2024, then surged by 901.47% to $2.7 billion in 2025, then sank by 96.34% to $100.0 million in 2026.
- Business Quant data shows NVS's Cash & Current Investments at $100.0 million in Q1 2026, $2.7 billion in Q4 2025, and $197.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 5.28 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 22.05 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 9.39 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 7.94 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 5.70 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 12.04 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 7.64 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 13.08 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 100.00 Mn |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 4.28 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 100.00 Mn |
| Dec 31, 2025 | 2.73 Bn |
| Jun 30, 2025 | 7.00 Bn |
| Mar 31, 2025 | 130.00 Mn |
| Dec 31, 2024 | -47.00 Mn |
| Sep 30, 2024 | 647.00 Mn |
| Jun 30, 2024 | 8.44 Bn |
| Dec 31, 2023 | 12.75 Bn |
| Jun 30, 2023 | 10.88 Bn |
| Dec 31, 2022 | 18.93 Bn |
| Sep 30, 2022 | -83.00 Mn |
| Jun 30, 2022 | 16.04 Bn |
| Dec 31, 2021 | 28.33 Bn |
| Sep 30, 2021 | 941.00 Mn |
| Jun 30, 2021 | -39.00 Mn |
| Mar 31, 2021 | -56.00 Mn |
| Dec 31, 2020 | 9.77 Bn |
| Sep 30, 2020 | 185.00 Mn |
| Jun 30, 2020 | 33.00 Mn |
| Mar 31, 2020 | 185.00 Mn |